摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 2-azido-3-(4-phenethyl-furan-2-yl)-acrylate | 1000402-23-2

中文名称
——
中文别名
——
英文名称
ethyl 2-azido-3-(4-phenethyl-furan-2-yl)-acrylate
英文别名
ethyl (Z)-2-azido-3-[4-(2-phenylethyl)furan-2-yl]prop-2-enoate
ethyl 2-azido-3-(4-phenethyl-furan-2-yl)-acrylate化学式
CAS
1000402-23-2
化学式
C17H17N3O3
mdl
——
分子量
311.34
InChiKey
CEOZSWLHUWRAHZ-WJDWOHSUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5
  • 重原子数:
    23
  • 可旋转键数:
    8
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    53.8
  • 氢给体数:
    0
  • 氢受体数:
    5

文献信息

  • FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE
    申请人:Heffernan L. R. Michele
    公开号:US20080004327A1
    公开(公告)日:2008-01-03
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR 1 and N. X and Y are members independently selected from O, S, CR 2 , N and NH. R 1 , R 2 and R 4 are members independently selected from H and F, provided that at least one member selected from R 1 , R 2 and R 4 is F. R 6 is a member selected from O − X + and OH, wherein X + is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.
    这项发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括该发明中化合物的药物组合物。该发明还提供了用于治疗和预防神经系统疾病,如神经精神病和神经退行性疾病,以及疼痛、共济失调和抽搐的方法。该发明中的化合物具有一般结构:其中A为NH或S。Q是从CR1和N中选择的成员。X和Y分别是从O、S、CR2、N和NH中独立选择的成员。R1、R2和R4是从H和F中独立选择的成员,前提是至少选择R1、R2和R4中的一个成员为F。R6是从O−X+和OH中选择的成员,其中X+是正离子,从无机正离子和有机正离子中选择的成员。
  • Fused heterocyclic inhibitors of D-amino acid oxidase
    申请人:Heffernan L. R. Michele
    公开号:US20080058395A1
    公开(公告)日:2008-03-06
    This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. Also provided are methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein Q is a member selected from O, S, CR 1 and N, X and Y are members independently selected from CR 2 , O, S, N and NR 3 .
    本发明提供了D-氨基酸氧化酶的新型抑制剂,以及包括该发明化合物的制药组合物。同时,还提供了治疗和预防神经系统疾病,如神经精神疾病和神经退行性疾病,以及疼痛、共济失调和惊厥的方法。该发明化合物具有以下一般结构:其中Q是从O、S、CR1和N中选择的成员,X和Y是独立选择自CR2、O、S、N和NR3的成员。
  • FUSED HETEROCYCLES
    申请人:Dorsey James M.
    公开号:US20100029741A1
    公开(公告)日:2010-02-04
    This invention provides methods of improving cognitive function by administering to a subject a therapeutically effective amount of a fused heterocycle having the formula: in which R 1 is a member selected from the group consisting of H, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 2 is a member selected from the group consisting of H substituted or unsubstituted alkenyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 3 is a member selected from the group consisting of H, C 1 -C 6 substituted or unsubstituted alkyl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl. R 4 is a member selected from OH and O − X + , in which X + is positive ion which is a member selected from organic positive ions and inorganic positive ions. Substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroarylalkyl moieties have the formula: in which Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. The index n is an integer from 1 to 4.
    本发明提供了通过向受试者给予具有以下公式的融合杂环的治疗有效量来提高认知功能的方法:其中R1是从H、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的成员。R2是从H、取代或未取代的烯基、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的成员。R3是从H、C1-C6取代或未取代的烷基、取代或未取代的芳基烷基和取代或未取代的杂芳基烷基组成的群体中选择的成员。R4是从OH和O-X+中选择的成员,其中X+是有机阳离子和无机阳离子中选择的成员中的正离子。取代或未取代的芳基烷基和取代或未取代的杂芳基烷基基团具有以下公式:其中Ar是从取代或未取代的芳基和取代或未取代的杂芳中选择的成员。指数n是1到4的整数。
  • FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE
    申请人:Sepracor Inc.
    公开号:EP2057162A2
    公开(公告)日:2009-05-13
  • US7579370B2
    申请人:——
    公开号:US7579370B2
    公开(公告)日:2009-08-25
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸